Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis
10.11665/j.issn.1000-5048.2023112904
- VernacularTitle:基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展
- Author:
Zhenzhen CUI
1
;
Yifan ZHAO
;
Yu SUN
;
Jiayi MENG
;
Di KANG
;
Lihong HU
Author Information
1. 南京中医药大学药学院, 江苏省中药功效物质重点实验室, 南京 210023
- Keywords:
CCL2;
CCR2;
cancer immunotherapy;
tumor microenvironment;
immunosuppressive cells
- From:
Journal of China Pharmaceutical University
2024;55(1):36-44
- CountryChina
- Language:Chinese
-
Abstract:
C-C motif chemokine ligand 2(CCL2)and its receptor CCR2 are closely related to tumorigenesis and tumor progression.The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms:CCL2 binds to CCR2 on the surface of tumor cells,and thus promotes tumor growth/survival and metastasis;more importantly,CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment,and inhibits the function and activity of immune cells,promoting tumor progression.The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment,with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis,in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.
